Last reviewed · How we verify
Pharmacokinetic based dosage change
This is a dosage adjustment strategy based on individual patient pharmacokinetic parameters rather than a specific drug entity.
At a glance
| Generic name | Pharmacokinetic based dosage change |
|---|---|
| Also known as | Factor VIII replacement therapy - non brand specific |
| Sponsor | Hampshire Hospitals NHS Foundation Trust |
| Modality | Small molecule |
| Phase | FDA-approved |
Mechanism of action
Pharmacokinetic-based dosage change refers to a clinical practice of individualizing drug doses according to measured or predicted drug concentrations and clearance rates in a patient. This approach aims to optimize therapeutic efficacy and minimize toxicity by accounting for patient-specific factors affecting drug absorption, distribution, metabolism, and elimination.
Approved indications
Common side effects
Key clinical trials
- Comparison of Target-Controlled and Manual Total Intravenous Anesthesia in Supratentorial Surgery (NA)
- A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation (PHASE2)
- Study of 5-fluorouracil (5-FU) in Patients With Metastatic Colorectal Cancer (PHASE2)
- Targeting Microenvironment and Cellular Immunity in Sarcomas Weekly Trabectedin Combined With Metronomic Cyclophosphamide (PHASE1, PHASE2)
- Rare Tumor Focused Platform Study of Innovative Therapies and Technologies (PLATFORM2) (PHASE1, PHASE2)
- MT2023-20: Hematopoietic Cell Transplant With Reduced Intensity Conditioning and Post-transplant Cyclophosphamide for Severe Aplastic Anemia and Other Forms of Acquired Bone Marrow Failure. (PHASE2)
- A Phase 1b Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Doses of JNJ-64565111 in Participants With Type 2 Diabetes Mellitus (PHASE1)
- Optimizing Hydroxyurea Dosage With Pharmakokinetic in Patients Suffering of Moderate to Severe Sickle Cell Anemia (PHASE2, PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: